Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 33Lymphoma 25Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 12Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Sarcoma 6Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Neutropenia 5Lymphoma, B-Cell, Marginal Zone 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Osteosarcoma 4Lung Neoplasms 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasm Metastasis 3

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × pegfilgrastim × Clear all
NCT00515411 2019-12-10

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
111 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡